This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free Online Activities

MAOIs: Issues in Treatment Adherence and Rates of Treatment Failure

Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP, FCP, and David A. Sclar, BPharm, PhD

Published: January 15, 2013

Article Abstract

Treatment guidelines recommend initiating newer antidepressants as first-line therapy for patients with depression, but response and remission rates remain low and multiple treatment trials are often needed. Adherence to medication affects response and remission rates, and nonadherence is common among patients with depression. While MAOIs have proven efficacy for depression, particularly for patients with treatment-resistant or atypical depression, this class of drugs is underprescribed due, in part, to concerns over dietary and drug restrictions that are required to avoid potential serious side effects. However, a newer MAOI formulation has an improved safety and tolerability profile and avoids or lessens the need for dietary restrictions, giving clinicians another option for treating patients who may be nonadherent or nonresponsive to their current antidepressant.

See the entire activity.


 

Volume: 74

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...